PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Evidence of elemene injection combined radiotherapy in lung cancer treatment among patients with brain metastases: A systematic review and meta-analysis.

Abstract This review evaluates the effectiveness and safety of elemene injection combined radiotherapy in the treatment of lung cancer with brain metastases.
PMID
Related Publications

Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer.

Chinese herbal medicine for oesophageal cancer.

Herbal extract elemene intrathoracic injection in the treatment of lung cancer patients with malignant pleural effusion: a meta-anaylsis.

Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Systematic review of β-elemene injection as adjunctive treatment for lung cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28538391
OWN - NLM
STAT- MEDLINE
DA  - 20170524
DCOM- 20170612
LR  - 20170612
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 21
DP  - 2017 May
TI  - Evidence of elemene injection combined radiotherapy in lung cancer treatment
      among patients with brain metastases: A systematic review and meta-analysis.
PG  - e6963
LID - 10.1097/MD.0000000000006963 [doi]
AB  - BACKGROUND: This review evaluates the effectiveness and safety of elemene
      injection combined radiotherapy in the treatment of lung cancer with brain
      metastases. METHODS: A systematic literature research was conducted from EMBASE, 
      Cochrane Library, PubMed, Chinese biomedical database, Chinese scientific journal
      database, China knowledge resource integrated database, and WanFang Database from
      established to July 2016 without language restriction. The Cochrane Collaboration
      tool was used to evaluate the risk of bias. All statistical analyses were
      conducted with STATA (version 14.0) and RevMan (version 5.3). RESULTS: Eleven
      randomized controlled trials (765 patients) were included for determining the
      effectiveness and safety of elemene combined with radiotherapy in the treatment
      of lung cancer with brain metastases. Objective response rate (ORR) [odds ratio
      (OR) = 2.89, 95% confidence interval (95% CI) 2.04-4.08, P < .00001] and symptoms
      (OR = 4.06, 95% CI 2.00-8.25, P = .0001) improved more in the elemene-based
      combination treatment group than in the radiotherapy-alone control group. The
      Karnofsky Performance Status (KPS) score was used to measure patients'
      improvement rate. The patients who were treated with elemene-based combination
      with radiotherapy were higher than those patients who were treated with
      radiotherapy alone (OR = 3.51, 95% CI 2.20-5.61, P < .00001]. The incidence of
      bone marrow suppression (OR = 0.27, 95% CI 0.11-0.68, P = .006) and leukopenia
      (OR = 0.23, 95% CI 0.12-0.46, P < .00001) decreased in the elemene-based
      combination treatment group by radiotherapy significantly. CONCLUSIONS: The
      elemene injection combined radiotherapy in the treatment of lung cancer with
      brain metastases appears to improve the treatment response rate and alleviated
      symptoms. The combined treatment has showed positive impact to reduce adverse
      reactions and improve quality of life.
FAU - Jiang, Xutao
AU  - Jiang X
AD  - aDepartment of Epidemiology and Biostatistics, School of Public Health, Dalian
      Medical University, Dalian, China bInstitute of Tropical Medicine, Nagasaki
      University, Nagasaki, Japan.
FAU - Hidru, Tesfaldet Habtemariam
AU  - Hidru TH
FAU - Zhang, Zhuo
AU  - Zhang Z
FAU - Bai, Yu
AU  - Bai Y
FAU - Kong, Lingchao
AU  - Kong L
FAU - Li, Xiaofeng
AU  - Li X
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Sesquiterpenes)
RN  - 11029-06-4 (elemene)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Brain Neoplasms/*secondary/*therapy
MH  - Chemoradiotherapy
MH  - Drugs, Chinese Herbal/administration & dosage
MH  - Humans
MH  - Injections
MH  - Lung Neoplasms/*pathology/*therapy
MH  - Randomized Controlled Trials as Topic
MH  - Sesquiterpenes/*administration & dosage
PMC - PMC5457871
EDAT- 2017/05/26 06:00
MHDA- 2017/06/13 06:00
CRDT- 2017/05/25 06:00
AID - 10.1097/MD.0000000000006963 [doi]
AID - 00005792-201705260-00032 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 May;96(21):e6963. doi: 10.1097/MD.0000000000006963.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>